Imipenem versus piperacillin/tazobactam for empiric treatment of neutropenic fever in adults | Zendy

Roohullah A. | Zendy; Moniwa A. | Zendy; Wood C. | Zendy; Humble M. | Zendy; Balm M. | Zendy; Carter J. | Zendy; Weinkove R. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Imipenem versus piperacillin/tazobactam for empiric treatment of neutropenic fever in adults

Author(s) -

Roohullah A.,

Moniwa A.,

Wood C.,

Humble M.,

Balm M.,

Carter J.,

Weinkove R.

Publication year - 2013

Publication title -

internal medicine journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.596

H-Index - 70

eISSN - 1445-5994

pISSN - 1444-0903

DOI - 10.1111/imj.12226

Subject(s) - medicine , piperacillin/tazobactam , cefepime , imipenem , piperacillin , tazobactam , neutropenia , clostridium difficile , empiric therapy , antibiotics , cohort , febrile neutropenia , intensive care medicine , chemotherapy , microbiology and biotechnology , antibiotic resistance , genetics , alternative medicine , pathology , bacteria , pseudomonas aeruginosa , biology

Australian guidelines for neutropenic fever recommend piperacillin/tazobactam ( PIP‐TAZ ) or cefepime for first‐line empiric treatment of neutropenic fever. We compared outcomes among haematology patients before and after changing our first‐line neutropenic fever treatment from imipenem to PIP‐TAZ . Forty‐five patients received imipenem and 60 PIP‐TAZ . Despite a higher rate of antibiotic modification in the PIP‐TAZ cohort, treatment success and time to defervescence were similar, with a trend towards fewer C lostridium difficile infections in the PIP‐TAZ cohort.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research